155 Results

People

  1. Perales
    Perales
  2. Brentjens
    Brentjens
  3. Park
    Park
  4. Palomba
    Palomba
  5. Sadelain
    Sadelain
  6. Shah
    Shah
  7. Shouval
    Shouval
  8. Riviere
    Riviere
  9. Dahi
    Dahi
  10. Salles
    Salles

Groups

  1. Department of Medicine (122)
  2. Hematologic Malignancies, Division of (122)
  3. Center for Hematologic Malignancies (115)
  4. GSK Faculty (64)
  5. Adult Leukemia (52)
  6. Hematologic Malignancies Research (51)
  7. Sloan Kettering Institute Faculty (44)
  8. Bone Marrow Transplant (41)
  9. Molecular Pharmacology and Chemistry Program Faculty (38)
  10. Sloan Kettering Institute Postdocs (31)
  1. "cd19 antigen"
Formats
  1. Journal Article (117)
  2. Review (25)
  3. Research Letter (5)
  4. Correspondence (4)
  5. Editorial (2)
  6. Guidelines (1)
  7. Miscellaneous (1)
Groups
  1. Department of Medicine (122)
  2. Hematologic Malignancies, Division of (122)
  3. Center for Hematologic Malignancies (115)
  4. GSK Faculty (64)
  5. Adult Leukemia (52)
  6. Hematologic Malignancies Research (51)

More Groups

People
  1. Michel Sadelain (32)
  2. Miguel-Angel Perales (32)
  3. Renier Brentjens (28)
  4. Jae Park (26)
  5. Gunjan Shah (17)
  6. Maria Palomba (17)

More People

Years
  1. 2025 (11)
  2. 2024 (14)
  3. 2023 (28)
  4. 2022 (21)
  5. 2021 (5)
  6. 2020 (12)

More Years

Publications
  1. Transplantation and Cellular Therapy (14)
  2. Blood (13)
  3. Leukemia and Lymphoma (10)
  4. Clinical Cancer Research (5)
  5. Leukemia (5)
  6. Journal of Clinical Oncology (4)

More Publications

Publishers
  1. Nature Publishing Group (29)
  2. Elsevier Inc. (23)
  3. American Society of Hematology (18)
  4. Taylor & Francis Group (12)
  5. American Association for Cancer Research (8)
  6. American Society of Clinical Oncology (6)

More Publishers

Results (155)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy
    Review

    Wudhikarn, K.; Perales, M. A.
    Bone Marrow Transplantation (2022)

    Fulltext@MSK | Save
  • NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia
    Research Letter

    Witkowski, M. T.; Lee, S.; Wang, E.; Lee, A. K.; Talbot, A.; Ma, C.; Tsopoulidis, N.; Brumbaugh, J.; Zhao, Y.; Roberts, K. G.; more...
    Nature Immunology (2022)

    Fulltext@MSK | Save
  • Role of CD19 chimeric antigen receptor T cells in second-line large B cell lymphoma: Lessons from phase 3 trials. An expert panel opinion from the American Society for Transplantation and Cellular Therapy
    Review

    Perales, M. A.; Anderson, L. D. Jr; Jain, T.; Kenderian, S. S.; Oluwole, O. O.; Shah, G. L.; Svoboda, J.; Hamadani, M.
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Real-world evidence of axicabtagene ciloleucel for the treatment of Large B cell lymphoma in the United States
    Journal Article

    Jacobson, C. A.; Locke, F. L.; Ma, L.; Asubonteng, J.; Hu, Z. H.; Siddiqi, T.; Ahmed, S.; Ghobadi, A.; Miklos, D. B.; Lin, Y.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • ASTCT Committee on Practice Guidelines survey on Evaluation & management of diffuse large B-cell lymphoma after failure of chimeric antigen receptor T cell therapy (CAR-T) therapy
    Journal Article

    Ahmed, N.; Kumar, A.; Kharfan-Dabaja, M. A.; DeFilipp, Z.; Herrera, A.; Hashmi, S.; Dholaria, B.; Perales, M. A.; Carpenter, P. A.; Hamadani, M.
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
    Journal Article

    Ghione, P.; Palomba, M. L.; Patel, A. R.; Bobillo, S.; Deighton, K.; Jacobson, C. A.; Nahas, M.; Hatswell, A. J.; Jung, A. S.; Kanters, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas
    Correspondence

    Fitzgerald, K. N.; Quesada, A. E.; von Keudell, G.; Raj, S.; Lewis, N. E.; Dogan, A.; Salles, G.; Palomba, M. L.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma
    Journal Article

    Kedmi, M.; Shouval, R.; Fried, S.; Bomze, D.; Fein, J.; Cohen, Z.; Danilesko, I.; Shem-Tov, N.; Yerushalmi, R.; Jacoby, E.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
    Journal Article

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K. V.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab
    Journal Article

    Wudhikarn, K.; King, A. C.; Geyer, M. B.; Roshal, M.; Bernal, Y.; Gyurkocza, B.; Perales, M. A.; Park, J. H.
    Blood Advances (2022)

    Fulltext@MSK | Save